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Abstract
Introduction: Preeclampsia remains one of the most common causes of maternal and perinatal mortality worldwide. 
A significant role in the pathogenesis of this pathology is assigned to placental ischemia and endothelial dysfunction. 
Therefore, the aim of the present study was to study the effectiveness of asialized erythropoietin and arginase II selec-
tive inhibitors: KUD-259 and KUD-974 in the correction of morphofunctional disorders of the cardiovascular system 
in experimental preeclampsia.
Materials and methods: The study was performed in 260 female Wistar rats, each weighing 250–300 g. An AD-
MA-like preeclampsia was reproduced in the experiment. To assess the emerging morphofunctional disorders, the fol-
lowing parameters were used: blood pressure, coefficient of endothelial dysfunction, microcirculation in the placenta, 
proteinuria, fluid content in the omentum, concentration of terminal metabolites in the blood plasma, and morphometric 
parameters of fetuses.
Results and discussion: The administration of arginase II selective inhibitor KUD-974 in combination with asialized 
erythropoietin leads to a pronounced correction of emerging changes: a decrease in systolic and diastolic blood pres-
sure in 1.5 and 1.7 times, a decrease in proteinuria in 3.6 times and a decrease in fluid content in the omentum. When 
arginase II selective inhibitor KUD 974 and asialized erythropoietin are used with methyldopa, the positive effects of 
the former are enhanced.
Conclusion: Arginase II selective inhibitors KUD-259 and KUD-974 and asialized erythropoietin have a pronounced 
positive effect on the correction of morphofunctional disorders in animals with ADMA-like preeclampsia.
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Introduction
The frequency of hypertensive pregnancy complicati-
ons is 5–30%, according to the Ministry of Health of the 
Russian Federation, while they occupy the fourth place 
in the structure of maternal mortality rate. From 2 to 8% 
of pregnancies are complicated by preeclampsia in the 
world, according to rough estimates (Alkema et al. 2016; 
Roberge et al. 2017; Conti-Ramsden et al. 2019). Hyper-
tensive disorders are the cause of the 16% of maternal 
losses in countires with high levels of socio-economic de-
velopment (Pankiewicz et al. 2019).
According to modern concepts, the development of 
preeclampsia is based on the disorder of the endothelium 
structural and functional state (Abalos et al. 2013; Kittur 
et al. 2013; Yanagawa et al. 2013). It arose as a result of 
placentation disorder on the background of incomplete 
remodeling of the uterine arteries, which ultimately leads 
to a decrease in blood supply and placental ischemia 
(George et al. 2017; Tomimatsu et al. 2019).
In spite of a huge amount of the studies conducted, the 
only method of treating this condition recognized by all 
experts is still timely delivery, aimed primarily at min-
imizing the threat to pregnant woman’s life. All other 
recommendations for the management of patients with 
preeclampsia can be reduced to the following principles: 
correction of hypovolemia, normalization of blood pres-
sure, restoration of the blood rheological properties, and 
prevention of the progression of endothelial dysfunction 
(Pankiewicz et al. 2019; Tomimatsu et al. 2019).
Nowadays, the only proven effective method for the 
prevention of preeclampsia is the administration of low 
doses of aspirin. A number of international recommenda-
tions, including those by WHO, state that after 12 weeks 
of pregnancy, aspirin is required at a dose of 75–100 mg 
per day. More recent studies concluded that the dose of 
aspirin should be more than 100 mg per day, and its ad-
ministration after 16 weeks of pregnancy had more ad-
vantages for the prevention of preeclampsia (Toppozada 
et al. 1991; Montfort et al. 2020).
Preclinical studies in L-NAME induced preeclampsia 
in rats demonstrated the positive effects of resveratrol (Zou 
et al. 2014), recombinant erythropoietin (Gureev 2016) 
and tadalafil (Yoshikawa et al. 2017). Another promising 
group of drugs for the treatment of hypertensive condi-
tions in pregnant women is arginase inhibitors (Nguyen et 
al. 2016; Severinova et al. 2019). At the same time, argin-
ase II inhibitors as being more selective are of particular 
interest (Pokrovskii et al. 2017; Gureev et al. 2015).
So, despite a wide range of drugs, objective reality dic-
tates the need to search for and study the effectiveness 
of new and currently existing drugs aimed at the preven-
tion and treatment of preeclampsia and its complications. 
There is evidence of endothelial protective properties of 
selective arginase II inhibitors KUD-259 and KUD-974 
(Pokrovskii et al. 2017); however, no studies of their ef-
fectiveness in experimental preeclampsia have been con-
ducted yet.
In view of the fact that placental ischemia is another 
component of the pathogenesis of preeclampsia (George 
et al. 2017; Tomimatsu et al. 2019), erythropoietin deriv-
atives not having an erythropoietic effect are a promising 
group of drugs in the treatment and prevention of preec-
lampsia (Mofidi et al. 2011; Ishii et al. 2012; Kaneko et 
al. 2013). These circumstances created the prerequisites 
for the present study.
Objective: To prove the effectiveness of asialized 
erythropoietin and selective arginase II inhibitors: KUD-
259 and KUD-974 in the correction of morphofunctional 
disorders of the cardiovascular system arising from ex-
perimental preeclampsia.
Materials and methods
The experimental study was conducted at the Research 
Institute of Pharmacology of Living Systems of Belgorod 
State National Research University. The study was per-
formed in compliance with the General Requirements for 
the Competence of Testing and Calibration Laboratories 
17025-2009, GOST R ISO 5725-2002 and the Rules of 
Laboratory Practice, approved by Order of the Ministry of 
Healthcare and Social Development of the Russian Federa-
tion dated August 23rd, 2010 № 708n. All the experiments 
were approved by the Ethical Committee of Belgorod State 
National Research University. Vivisection was performed 
in compliance with the ethical principles of treating labora-
tory animals of the European Convention for the Protection 
of Vertebrates Used for Experimental and Other Scientific 
Purposes. CETS No. 123 (European Treaty Series 1986).
ADMA-like preeclampsia was simulation. The study 
was performed in 260 female Wistar rats, each weigh-
ing 250–300 g. ADMA-like preeclampsia was simulat-
ed by administration of a nonselective eNOS blocker 
N-nitro-L-arginine methyl ether (L-NAME) at a dose of 
25 mg/kg/day intraperitoneally from the 14th to 20th day 
of pregnancy. One day after the last injection under an-
esthesia (chloral hydrate 300 mg/kg), hemodynamic pa-
rameters were recorded, and the endothelial function was 
studied using a sensor and a hardware complex for inva-
sive measurement of hemodynamic parameters by Biopac 
(USA) and the AcqKnowledge 3.8.1 computer software 
(Stupakova et al. 2019).
Assessment of an endothelial dysfunction degree 
in the simulated pathology. Endothelial dysfunction 
was evaluated by calculating a coefficient of endothelial 
dysfunction (CED), which is the ratio of endothelium-de-
pendent vaso-relaxation (acetylcholine) and endotheli-
um-independent vaso-relaxation (sodium nitroprusside) 
(Korokin et al. 2019).
Estimation of the terminal NO metabolites. The lev-
el of NO metabolites (that is the total concentration of 
nitrates and nitrites, NOx) was determined by the color-
imetric method, according to the staining pattern in the 
diazotization reaction of sulfonamide nitrite, which is a 
part of the reagent (Stupakova et al. 2019).
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Analysis of the placental microcirculation. Microcir-
culation in the placenta was measured using Biopac sys-
tems equipment: an MP100 polygraph with laser Doppler 
flowmetry module (LDF) LDF100C and an invasive needle 
probe TSD144 (Korokin et al. 2015), which was mounted 
directly in the projection of the placental disk. Registration 
and processing of LDF results were carried out using Ac-
qKnowledge 3.8.1 software; microcirculation values were 
expressed in perfusion units (PU) (Gureev 2016).
The study of swelling of the omentum. To study the 
liquid content in the omentum, it was weighed, followed 
by drying at 37 °C for 24 hours and another weighing.
Morphological methods for assessing changes in the 
placenta and kidneys in ADMA-like preeclampsia. A 
histological examination (in all series of the experiment) 
of the kidneys and placenta was performed for morpholog-
ical confirmation of the development of simulated patho-
logical processes and in a comprehensive assessment of 
the drugs effectiveness. The material was fixed in 10% 
formalin, followed by paraffin embedding. The kidneys 
were sliced perpendicular to the main axis of the organ 
through the pelvis. Histological sections of the placenta 
were performed in a strictly vertical direction through the 
middle of the placental disc, capturing all layers of the 
placenta and the walls of the uterine horn. The study of the 
slides, photoprotocoling and morphometry were carried 
out using a Leica DM4000B microscope with a video re-
cording and image processing system. For all the morpho-
logical studies, hematoxylin and eosin staining was used.
The study of embryos. The embryos were removed 
from the uterine cavity; their weight and growth (cranio-
caudal size) were measured, followed by calculating the 
growth-weight coefficient.
Statistical processing of the research results. De-
scriptive statistics were applied to all the data. The data 
were checked for normal distribution. The type of dis-
tribution was determined by the Shapiro-Wilk criterion. 
In the case of a normal distribution, the mean value (M) 
and the standard error of the mean (m) were calculated. 
The intergroup differences were analyzed using Student’s 
t-test or Mann-Whitney U-test, depending on the type of 
distribution. The statistical significance of the differences 
between morphological changes after their ranking was 
evaluated using Mann-Whitney nonparametric method of 
data analysis. All the calculations were performed using a 
Microsoft Excel 7.0 statistical package.
Experiment design
According to the objective, all animals were divided into 
the following groups:
1. Control group (animals with oral administration of 
NaCl at equivalent doses from the 14th to 20th -day 
of pregnancy).
2. Simulation of experimental preeclampsia (L-NAME 
(25 mg/kg once daily intraperitoneally) from the 
14th to the 20th day of pregnancy).
3. Simulation of experimental preeclampsia + meth-
yldopa (2 × 0.043 g/kg twice a day intragastrically)
4. Simulation of experimental preeclampsia + recom-
binant erythropoietin (50 IU/kg/day intraperitoneal-
ly, on days 7, 10, 13, 16, and 19).
5. Simulation of experimental preeclampsia + asialized 
erythropoietin (0.4 μg/kg/day intraperitoneally).
6. Simulation of experimental preeclampsia + asialized 
erythropoietin (2.4 μg/kg/day intraperitoneally).
7. Simulation of experimental preeclampsia + L-Nor-
valine (10 mg/kg/day intragastrically).
8. Simulation of experimental preeclampsia + selec-
tive arginase II inhibitor KUD-259 (1 mg/kg/day 
intragastrically).
9. Simulation of experimental preeclampsia + selec-
tive arginase II inhibitor KUD-974 (1 mg/kg/day 
intragastrically).
10. Simulation of experimental preeclampsia + meth-
yldopa (2 × 0.043 g/kg twice a day intragastrically) + 
asialized erythropoietin (2.4 μg/kg/day intraperitone-
ally).
11. Simulation of experimental preeclampsia + meth-
yldopa (2 × 0.043 g/kg twice a day intragastrically) 
+ selective arginase II inhibitor KUD-974 (1 mg/kg/
day intragastrically).
12. Simulation of experimental preeclampsia + asial-
ized erythropoietin (2.4 μg/kg/day intraperitoneal-
ly) + selective arginase II inhibitor KUD-974 (1 mg/
kg/day intragastrically).
Results and discussion
Effect of asialized erythropoietin on morphofunctional 
disorders resulting from experimental preeclampsia
Female white Wistar rats, each weighing 250–300 g, 
were used in the experiment. To simulate experimental 
preeclampsia, N-nitro-L-arginine methyl ether (L-NA-
ME), which has the biological properties similar to tho-
se of asymmetric dimethylargenin (ADMA) – an eNOS 
blockade – was administered at a dose of 25 mg/kg intra-
peritoneally from the 14th to 20th day of pregnancy. This 
resulted in a statistically significant (p < 0.05) increase in 
systolic and diastolic blood pressure from 123.2 ± 3.46 
and 76.3 ± 5.71 to 194.8 ± 7.88 and 149.8 ± 4.73 mmHg, 
respectively, in comparison with the group of the intact 
animals (Table 1).
Administration of asialized erythropoietin to the an-
imals with experimental preeclampsia at a dose of 0.4 
μg/kg/day intraperitoneally did not lead to a statistical-
ly significant decrease in blood pressure. A statistically 
significant (p < 0.05) decrease in systolic and diastolic 
blood pressure to 167.3 ± 3.43 and 129.4 ± 4.17 mmHg 
was observed when administering asialized erythropoi-
etin intraperitoneally at a dose of 2.4 μg/kg/day to the 
animals with experimental preeclampsia, but it did not 
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reach the target level. It is worth noting that the intensity 
of the hypotensive effect of asialized erythropoietin was 
comparable with the hypotensive effect of recombinant 
erythropoietin, but was inferior to the hypotensive effect 
of methyldopa, a drug used in the treatment of hyperten-
sive conditions in pregnant rats.
Simulation of experimental preeclampsia was accom-
panied by a change in the rate of reactions to vasodilat-
ing humoral factors, which indicated the disorder of the 
regulatory mechanisms of vascular tone and is explained 
by the resulting endothelial dysfunction. The coefficient 
of endothelial dysfunction (CED) increased from 1.21 ± 
0.08 (intact animals) to 3.17 ± 0.22 relative units. Admin-
istration of asialized erythropoietin to the animals with 
experimental preeclampsia at a dose of 0.4 μg/kg/day and 
2.4 μg/kg/day intraperitoneally led to a statistically signif-
icant (p < 0.05) decrease in CED to 2.09 ± 0.14 and 1.67 
± 0.12 relative units, respectively, but CED did not reach 
the target level. This indicates a decrease in violations of 
the mechanisms controlling blood pressure.
It is important to emphasize that a decrease in CED 
under the influence of asialized erythropoietin at a dose of 
0.4 μg/kg/day was comparable with the effect of recombi-
nant erythropoietin and exceeded the effect of methyldo-
pa, a comparative drug for the treatment of hypertensive 
disorders in pregnant rats. The decrease in СED under the 
influence of asialized erythropoietin at a dose of 2.4 μg/
kg/day was more pronounced than the effect of both com-
parison drugs.
In the animals with experimental preeclampsia, a sta-
tistically significant (p < 0.05) decrease in the placenta 
microcirculation was observed from 493 ± 21.1 perfusion 
units (PU) (intact animals) to 201 ± 6.0 PU. The admin-
istration of asialized erythropoietin to the animals with 
experimental preeclampsia at a dose of 0.4 μg/kg/day and 
2.4 μg/kg/day intraperitoneally led to a statistically signif-
icant (p < 0.05) increase in the placenta microcirculation 
to 357 ± 22.7 PU and 413 ± 20.0 PU, respectively, but 
did not reach the target level. However, it is of impor-
tance that under the influence of asialized erythropoietin 
at both doses, the improvement in microcirculation was 
more pronounced in comparison with the effects of both 
comparison drugs (Table 1).
A biochemical study showed that the simulation of ex-
perimental preeclampsia led to a decrease in the final NO 
metabolites in plasma from 2.23 ± 0.04 μmol/dl (in intact 
animals) to 1.25 ± 0.01 μmol/dl (Fig. 1A). The admin-
istration of asialized erythropoietin to the animals with 
experimental preeclampsia at a dose of 0.4 μg/kg/day and 
2.4 μg/kg/day intraperitoneally led to a statistically sig-
nificant (p < 0.05) increase in this indicator to 1.49 ± 0.02 
μmol/dl and 1.61 ± 0.02 μmol/dl, respectively, but it did 
not reach the target level.
Simulated preeclampsia did not change the daily di-
uresis, but it led to a statistically significant (p < 0.05) 
increase in proteinuria compared with the intact pregnant 
animals from 0.18 ± 0.05 g/L to 2.02 ± 0.20 g/L (Fig. 1B). 
The administration of asialized erythropoietin at a dose of 
0.4 μg/kg/day and 2.4 μg/kg/day intraperitoneally led to a 
statistically significant (p < 0.05) decrease in protein in the 
urine to 1.4 ± 0.06 g/L and 1.03 ± 0.08 g/L, respectively.
A study of the liquid content in the omentum of the 
animals with experimental preeclampsia revealed its in-
crease (p < 0.05) compared with the intact pregnant ani-
mals from 44.20 ± 1.08% to 54.27 ± 0.64%. The admin-
istration of asialized erythropoietin at the studied doses 
led to a decrease in the level of swelling of the omentum 
tissues (p < 0.05) to 49.89 ± 0.75% and 48.73 ± 0.81%, 
respectively, but it did not reach the target level. The liq-
uid content in the omentum decreased in the animals with 
ADMA-like preeclampsia treated with methyldopa and 
recombinant erythropoietin (p < 0.05) to 50.51 ± 0.57% 
and 50.74 ± 0.51%, respectively.
A histological study of placental microsections in 
the group of intact animals on the 21st day of gestation 
revealed two well-visualized parts of the placenta: fetal 
and maternal. A microscopic examination of the histolog-
ical sections of the placenta in the animals with experi-
mental preeclampsia revealed distinct signs of destruc-
tive-dystrophic changes in the placenta. The administration 
of the studied pharmacological agents for the correction of 
experimental preeclampsia led to positive dynamics with 
the pronounced effect in the group of animals treated with 
asialized erythropoietin at a dose of 2.4 μg/kg/day.
The results of the study of the features of fetal de-
velopment in the animals with ADMA-like preeclamp-
sia revealed fetal malnutrition (Table 2). The fetal mass 
changed to a greater extent. The most accurate indicator 
reflecting this pattern is the fetal height-to-weight ratio, 
which statistically significantly increased for these em-
Table 1. Experimental results of the correction of experimental preeclampsia with asialized erythropoietin in rats (M ± m; N = 10).
Indicator
Group SBP, mm hg DBP, mm hg CED, cond. un. Microcircula-tion, PU
Intact 123.2 ± 3.46y 76.3 ± 5.71y 1.21 ± 0.08y 493 ± 21.1y
L-NAME 194.8 ± 7.88* 149.8 ± 4.73* 3.17 ± 0.22* 212 ± 6.0*
Methyldopa (2× 0.043 g/kg) 134.9 ± 1.89y* 102.0 ± 3.71y* 2.51 ± 0.18y* 272 ± 12.2y*
EPo (50 IU/kg) 179.3 ± 3.84y* 133.4 ± 2.62y* 2.12 ± 0.21y* 301 ± 10.1y*
AsEPo (0.4 μg/kg) 183.1 ± 6.71y* 139.7 ± 3.72y* 2.09 ± 0.14y* 357 ± 22.6y*
AsEPo (2.4 μg/kg) 167.3 ± 3.43y* 129.4 ± 4.17y* 1.67 ± 0.12y* 413 ± 20.0y*
Note: SBP, DBP – systolic and diastolic blood pressure (mmHg); CED – coefficient of endothelial dysfunction; EPo – recombinant erythropoietin; 
AsEPo – asialized erythropoietin; PU – perfusion units; * – p < 0.05 in comparison with the group of intact animals; y – p < 0.05 compared with the 
L-NAME group.
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bryos. No post-implantation deaths were observed in any 
groups. The administration of the studied pharmacologi-
cal agents led to positive dynamics, namely an increase 
in the mass of the fetus, though the level of the intact ani-
mals was not reached.
Effect of selective arginase II inhibitors: KUD-259 and 
KUD-974 on morphofunctional disorders in experi-
mental preeclampsia
The administration of arginase II selective inhibitors: 
KUD-259 and KUD-974 – to the animals with expe-
rimental preeclampsia led to a statistically significant 
(p < 0.05) decrease in blood pressure compared with the 
group of the untreated animals only under the influence of 
KUD-974 (Table 3).
The use of arginase II selective inhibitors in the an-
imals with ADAM-like preeclampsia: KUD-259 and 
KUD-974 – at a dose of 1 mg/kg/day orally led to a sta-
tistically significant (p < 0.05) decrease in CED to 1.53 ± 
0.10 and 1.70 ± 0.12 relative units, respectively, but did 
not reach the target level. This indicates a decrease in vio-
lations of the mechanisms controlling blood pressure. It is 
of importance that a decrease in CED under the influence 
of arginase II selective inhibitors: KUD-259 and KUD-
974 – at a dose of 1 mg/kg/day was comparable with the 
effect of the non-selective arginase II inhibitor – L-Nor-
valine – and exceeded the effect of the comparison drug 
included in the treatment regimen of hypertensive condi-
tions in pregnant – methyldopa.
In the animals with experimental preeclampsia, the ad-
ministration of arginase II selective inhibitors: KUD-259 
and KUD-974 – at a dose of 1 mg/kg/day intragastrical-
ly led to a statistically significant (p < 0.05) increase in 
the placenta microcirculation to 410 ± 18.7 PU and 394 ± 
24.4 PU, respectively, but did not reach the target level. 
However, it is worth noting that under the influence of 
both arginase II selective inhibitors: KUD-259 and KUD-
974, the improvement of microcirculation was compara-
ble to the effect of the non-selective arginase II inhibitor 
– L-Norvaline – and was more pronounced in comparison 
with the drugs included in the treatment standards for hy-
pertensive conditions in pregnant women (Table 3).
A biochemical study found that the administration of 
arginase II selective inhibitors: KUD-259 and KUD-974 
at a dose of 1 mg/kg/day intragastrically to the animals 
with experimental preeclampsia led to a statistically sig-
nificant (p < 0.05) increase in the content of terminal NO 
metabolites in blood plasma up to 1.60 ± 0.02 μmol/dl and 
1.80 ± 0.03 μmol/dl, respectively, but it did not reach the 
target level (Fig. 2A).
The administration of arginase II selective inhibitors: 
KUD-259 and KUD-974 – to the pregnant animals with 
experimental preeclampsia did not lead to a change in di-
uresis, but led to a decrease in proteinuria (p < 0.05) to 
0.76 ± 0.08 g/L and 0.89 ± 0.08 g/L, respectively.
The use of arginase II selective inhibitors: KUD-259 
and KUD-974 – led to a decrease in the level of swelling 
of the omentum tissues (p < 0.05) to 49.30 ± 0.26% and 
48.92 ± 0.68%, respectively, but the target level was not 
Table 2. Effect of asialized erythropoietin on statural-weight values of fetal development in ADMA-like preeclampsia (M ± m; N = 20).
Group IndicatorWeight of embryos, g Stature of embryos, mm Statural- weight value, mm/g
Intact 1.69 ± 0.03y 24.65 ± 0.37 14.57 ± 0.13y
L-NAME 1.47 ± 0.03* 23.95 ± 0.40 16.33 ± 0.10*
Methyldopa (2 × 0.043 g/kg) 1.52 ± 0.02* 23.80 ± 0.28 15.65 ± 0.08y*
EPo (50 IU/kg) 1.54 ± 0.03* 24.25 ± 0.47 15.73 ± 0.09y*
AsEPo (0.4 μg /kg) 1.54 ± 0.03* 24.20 ± 0.45 15.72 ± 0.09y*
AsEPo (2.4 μg /kg) 1.63 ± 0.03y 24.80 ± 0.40 15.20 ± 0.09y*
Note: * – p < 0.05 in comparison with the group of intact animals; y – p < 0.05 compared with the L-NAME group; EPo – recombinant erythropoietin; 
AsEPo – asialized erythropoietin.
Figure 1. Effect of asialized eryropoietin on the concentration of final nitric oxide metabolites in plasma during experimental pre-
eclampsia (A), proteinuria (B). Note: * – p < 0.05 in comparison with the group of intact animals; y – p < 0.05 compared with the 
L-NAME group; EPo – recombinant erythropoietin; AsEPo - asialized erythropoietin.
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reached. When the animals with ADMA-like preeclamp-
sia were administered with L-Norvaline, the fluid content 
in the omentum tissues was 49.57 ± 0.70%.
After the pharmacological correction, there was a pos-
itive dynamics of the previously detected reactive mor-
phological changes in the placenta structures on the 21st 
day of gestation during experimental preeclampsia in all 
the experimental groups . The most pronounced positive 
effects were observed in the group of the animals treated 
with arginase II selective inhibitor KUD-794.
The administration of the studied arginase II selective 
inhibitors: KUD-259 and KUD-974 – led to an increase in 
fetal weight in the animals with ADMA-like preeclamp-
sia, but the level of the intact animals was not reached 
(Table 4).
Effect of the combination of asialized erythropoietin 
and selective arginase II KUD-974 inhibitor and their 
combined use with methyldopa on morphofunctional 
disorders in ADMA-like pre-eclampsia
The administration of asialo-EPO and arginase II selec-
tive inhibitor KUD-974 in combination with a standard 
therapy of hypertensive conditions methyldopa in the 
pregnant animals with experimental preeclampsia led to 
a statistically significant (p < 0.05) decrease in systolic 
and diastolic blood pressure compared with the group of 
the untreated animals (Table. 5). It is important to note 
that the use of arginase II selective inhibitor KUD-974 in 
combination with methyldopa decreased systolic and dia-
stolic blood pressure to the level not statistically different 
from that in the group of the intact animals. In the group 
of the animals treated with asialo-EPO and methyldopa, 
only systolic pressure decreased to the level statistically 
indistinguishable in comparison with the group of the in-
tact animals.
The combined use of asialized erythropoietin and ar-
ginase II selective inhibitor KUD-974 led to a statistically 
significant (p < 0.05) decrease in systolic and diastolic 
blood pressure compared with the group of the untreat-
ed animals, while the level of diastolic pressure was not 
statistically indistinguishable from the group of intact an-
imals. A decrease in blood pressure in the combined use 
of the pharmacological agents to the level statistically in-
distinguishable from the group of the intact animals can 
be regarded as potentiation of their action, since this was 
not observed in the monotherapy.
The use of a combination of asialized erythropoietin 
with arginase II selective inhibitor KUD-974 in the ani-
mals with experimental preeclampsia, and their combina-
tion with methyldopa, led to a more pronounced decrease 
in CED compared with groups of the animals where these 
pharmacological agents were used as a monotherapy (Ta-
ble 5). In all the groups with combined use of the studied 
pharmacological agents, CED reached the level of that in 
the intact animals.
The administration of asialized erythropoietin and 
arginase II selective inhibitor KUD-974 in combination 
Table 3. Correction results of experimental preeclampsia with arginase II selective inhibitors: KUD-259 and KUD-974 (M ± m; 
N = 10).
Group  IndicatorSBP, mm Hg DBP, mm Hg CED, relative units. Microcircula-tion, PU
Intact 123.2 ± 3.46y 76.3 ± 5.71y 1.21 ± 0.08y 493 ± 21.1y
L-NAME 194.8 ± 7.88* 149.8 ± 4.73* 3.17 ± 0.22* 212 ± 6.0*
Methyldopa (2 × 0.043 g/kg) 134.9 ± 1.89y* 102.0 ± 3.71y* 2.51 ± 0.18y* 272 ± 12.2y*
L-Norvaline (10 mg/kg) 201.3 ± 2.89* 153.4 ± 3.27* 1.81 ± 0.12y* 406 ± 19.8y*
KUD-259 (1 mg/kg) 195.8 ± 5.52* 144.9 ± 6.88* 1.53 ± 0.10y* 410 ± 18.7y*
KUD-974 (1 mg/kg) 148.1 ± 2.96y* 105.7 ± 4.85y* 1.70 ± 0.12y* 394 ± 24.4y*
Note: SBP, DBP – systolic and diastolic blood pressure (mmHg); CED – coefficient of endothelial dysfunction; PU – perfusion units; * – p < 0.05 in 
comparison with the group of intact animals; y – p < 0.05 compared with the L-NAME group.
Figure 2. The effect of arginase II selective inhibitors: KUD-259 and KUD-974 – on the concentration of terminal nitric oxide 
metabolites (A) in plasma and proteinuria during experimental preeclampsia (B). Note: * – p < 0.05 in comparison with the group 
of the intact animals; y – p < 0.05 compared with the L-NAME group.
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with methyldopa, as well as a combination of asialized 
erythropoietin and arginase II selective inhibitor KUD-
974 to the animals with experimental preeclampsia, led to 
an improvement in placental microcirculation to the level 
of the intact animals (Table 5).
A biochemical study of the concentration of terminal 
NO metabolites in plasma revealed a statistically signifi-
cant increase (Fig. 3A) with the administration of asialized 
erythropoietin and arginase II selective inhibitor KUD-974 
in combination with methyldopa, as well as with the com-
bined use of asialized erythropoietin and arginase II selec-
tive inhibitor KUD-974. Moreover, it is important to note 
that this indicator in the described experimental groups 
reached the level of that in the intact animals.
The use of asialized erythropoietin and arginase 
II selective inhibitor KUD-974 in combination with 
methyldopa, as well as a combination of asialized eryth-
ropoietin and arginase II selective inhibitor KUD-974 
in the animals with experimental preeclampsia, led to a 
statistically significant decrease in protein concentration 
in the urine. At the same time, proteinuria in the groups 
with combined use of the studied pharmacological agents 
decreased to a level comparable to that in the group of the 
intact animals. No changes in diuresis in the described 
experimental groups were observed.
When assessing the fluid content in the omentum, a 
statistically significant (p < 0.05) decrease was revealed 
with the administration of asialized erythropoietin and 
arginase II selective inhibitor KUD-974 in combination 
with methyldopa to 44.25 ± 0.87% and 43.24 ± 1.31%, 
respectively, as well as with the combined use of asial-
ized erythropoietin and arginase II selective inhibitor 
KUD-974 (41.95 ± 0.88%). Moreover, it is of importance 
that this indicator in the described experimental groups 
reached the level of that in the intact animals.
A histological examination of the placenta showed that 
the administration of asialized erythropoietin and argin-
ase II selective inhibitor KUD-974 in combination with 
methyldopa, as well as a combination of asialized eryth-
ropoietin and arginase II selective inhibitor KUD-974 in 
the animals with experimental preeclampsia, led to pro-
nounced positive dynamics of the morphological pattern 
comparable with that in the group of the intact animals.
The results of the study of the fetal development in the 
animals with ADMA-like preeclampsia treated with the 
combination of asialized erythropoietin and arginase II se-
lective inhibitor KUD-974 with methyldopa, as well as the 
combination of asialized erythropoietin and arginase II se-
lective inhibitor KUD-974 revealed an increase in embry-
os’ weight (Table 6). In both groups in which the combined 
therapy included arginase II selective inhibitor KUD-974, 
the fetal weight reached the level of the intact animals.
Thus, the results of the experiments indicate a pro-
nounced protective activity of asialized erythropoietin and 
arginase II selective inhibitor KUD-974 in combination 
with methyldopa, as well as the combined use of asialized 
Table 4. Effect of arginase II selective inhibitors: KUD-259 and KUD-974 – on statural-weight value of fetal development with 
ADMA-like preeclampsia (M ± m; N = 20).
Group Indicator
Weight of embryos, g Stature of embryos, mm Statural-weight value, mm / g
Intact 1.69 ± 0.03y 24.65 ± 0.37 14.57 ± 0.13y
L-NAME 1.47 ± 0.03* 23.95 ± 0.40 16.33 ± 0.10*
L-NAME + L-Norvaline 1.58 ± 0.03y* 24.45 ± 0.53 15.51 ± 0.06y*
L-NAME + Methyldopa 1.52 ± 0.02* 23.80 ± 0.28 15.65 ± 0.08y*
L-NAME + KUD-259 1 mg/kg/day 1.60 ± 0.02y* 24.30 ± 0.31 15.16 ± 0.10y*
L-NAME + KUD-974 1 mg/kg/day 1.61 ± 0.03y* 24.20 ± 0.39 15.07 ± 0.08y*
Note: * – p < 0.05 in comparison with the group of the intact animals; y – p < 0.05 compared with the L-NAME group.
Table 5. Effect of asialized erythropoietin and arginase II selective inhibitor KUD-974 Combined with Methyldopa, as well as the 
combined use of asialized erythropoietin and arginase II selective inhibitor KUD-974 on functional parameters in experimental 
preeclampsia (M ± m; N = 10).
Group IndicatorSBP, mm Hg DBP, mm Hg. CED, relative units Microcircu-lation, PU
Incact 123.2 ± 3.46y 76.3 ± 5.71y 1.21 ± 0.08y 493 ± 21.1y
L-NAME 194.8 ± 7.88* 149.8 ± 4.73* 3.17 ± 0.22* 212 ± 6.0*
Methyldopa (2 × 0.043 g/kg) 134.9 ± 1.89y* 102.0 ± 3.71y* 2.51 ± 0.18y* 272 ± 12.2y*
AsEPo (2.4 μg/kg) 167.3 ± 3.43y* 129.4 ± 4.17y* 1.67 ± 0.12y* 413 ± 20.0y*
KUD-974 (1 mg/kg) 148.1 ± 2.96y* 105.7 ± 4.85y* 1.70 ± 0.12y* 394 ± 24.4y*
KUD-974 + Methyldopa 130.9 ± 4.43y 91.4 ± 5.07y 1.36 ± 0.10y 492 ± 15.8y
AsEPo + Methyldopa 130.1 ± 3.70y 97.4 ± 4.93y* 1.44 ± 0.12y 480 ± 10.9y
AsEPo + KUD-974 133.0 ± 2.50y* 88.1 ± 6.45y 1.30 ± 0.12y 481 ± 16.8y
Note: SBP, DBP – systolic and diastolic blood pressure (mmHg); CED – coefficient of endothelial dysfunction (relative units); PU – perfusion 
units; EPo – recombinant erythropoietin; AsEPo – asialized erythropoietin; * – p < 0.05 in comparison with the group of intact animals; y – p < 0.05 
compared with the L-NAME group.
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erythropoietin and arginase II selective inhibitor KUD-974 
on correction of morphofunctional disorders that occur in 
animals with simulated preeclampsia. It is worth noting 
that the used combinations provide a more pronounced 
correction of morphofunctional disorders compared to us-
ing each drug from this combinations as a monotherapy.
Conclusion
One of the foundations of the modern concept of the de-
velopment of preeclampsia is a violation of the structural 
and functional states of the endothelium (Pankiewicz et 
al. 2019; Tomimatsu et al. 2019) as a result of placenta-
tion disorder on the background of incomplete remode-
ling of the uterine arteries, which ultimately leads to a 
decrease in blood supply and placental ischemia (George 
et al. 2017; Tomimatsu et al. 2019). The endothelium is a 
powerful endocrine organ involved in regulating vascular 
tone and maintaining their normal structure, monitoring 
the rheological properties of blood and local inflammati-
on. One of the manifestations of the development of en-
dothelial dysfunction is a deficiency of nitric oxide (NO), 
which is a powerful vasodilator (Aouache et al. 2018; 
Than et al. 2018).
Another important factor in endothelial dysfunction is 
ischemia. Endothelial cells, in comparison with other cells 
of the body, are quite resistant to ischemia. It is assumed 
that during ischemia, endotheliocytes switch to anaerobic 
energy metabolism and also produce heat shock proteins, 
glyceraldehyde-3-phosphate dehydrogenase enzymes and 
non-neuronal enolase, which are involved in glycolysis, 
which in turn increase cell resistance to damage (Lutsen-
ko et al. 2015). However, hypoxia alters the expression of 
a number of genes involved in the regulation of vascular 
tone, which leads to a shift in the balance between vaso-
dilation and vasoconstriction towards the latter. Besides, 
under conditions of hypoxia, the activity of phospholipas-
es A and C, diacylglycerol lipase, increases; the cascade 
of arachidonic acid is launched, and the concentration of 
its derivatives increases, which also affect vascular tone.
One of the promising groups of drugs for the treatment 
of preeclampsia are arginase inhibitors. At present, a great 
deal of data has been accumulated on their pronounced 
endothelial protective properties, including those obtained 
using various experimental models of preeclampsia (Gu-
reev 2016; Nguyen et al. 2016). Arginase II inhibitors are 
of particular interest, as being more selective. The pre-
clinical studies of the selective arginase II inhibitor ZB49-
0010 in various pathology models showed its pronounced 
Table 6. Effect of asialized erythropoietin and arginase II selective inhibitor KUD-974 in combination with Methyldopa, as well 
as the combined use of asialized erythropoietin and arginase II selective inhibitor KUD-974 on fetal statural-weight values in AD-
MAc-like preeclampsia (M ± m; N = 20).
Group Indicator
Weight of embryos, g Stature of embryos, mm Statural-weight value, mm/g
Intact 1.69 ± 0.03y 24.65 ± 0.37 14.57 ± 0.13y
L-NAME 1.47 ± 0.03* 23.95 ± 0.40 16.33 ± 0.10*
Methyldopa (2 × 0,043 g/kg) 1.52 ± 0.02* 23.80 ± 0.28 15.66 ± 0.08y*
AsEPo (2.4 μg /kg) 1.63 ± 0.03y 24.80 ± 0.40 15.20 ± 0.09y*
KUD-974 (1 mg/kg) 1.61 ± 0.03y* 24.20 ± 0.39 15.06 ± 0.08y*
KUD-974 + Methyldopa 1.62 ± 0.03y 23.95 ± 0.52 14.81 ± 0.10y
AsEPo + Methyldopa 1.62 ± 0.02y 24.20 ± 0.40 14.94 ± 0.10y*
AsEPo + KUD-974 1.65 ± 0.03y 24.30 ± 0.41 14.78 ± 0.09y
Note: * – p < 0.05 in comparison with the group of intact animals; y – p < 0.05 compared with the L-NAME group; EPo – recombinant erythropoietin; 
AsEPo – asialized erythropoietin.
Figure 3. The effect of asialized erythropoietin and arginase II selective inhibitor KUD-974 in combination with methyldopa, as well 
as the combined use of asialized erythropoietin and arginase II selective inhibitor KUD-974 on the concentration of terminal nitric 
oxide metabolites in plasma (A) and proteinuria (B) in experimental preeclampsia. Note: * – p < 0.05 in comparison with the group of 
intact animals; y – p < 0.05 compared with the L-NAME group; EPo – recombinant erythropoietin; AsEPo – asialized erythropoietin.
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endothelial protective properties that are superior to those 
for the non-selective inhibitor of L-norvaline (Gureev et 
al. 2015; Nguyen et al. 2016; Severinova et al. 2019). The 
literature contains data on the endothelial protective prop-
erties of arginase II selective inhibitors KUD-259 and 
KUD-974 on the functional state of vascular endothelium 
(Pokrovskii et al. 2017); however, to date, studies of their 
effectiveness have not been conducted in experimental 
preeclampsia yet.
Thus, it becomes obvious that short-lived erythropoi-
etin derivatives that do not have an erythropoietic effect 
and selective arginase II inhibitors can serve as another 
promising area for searching for new drugs to prevent and 
correct preeclampsia. In this regard, the purpose of this 
study was to prove the effectiveness of asialized eryth-
ropoietin and arginase II selective inhibitors: KUD-259 
and KUD-974 – in the correction of morphofunctional 
disorders of the cardiovascular system arising from ex-
perimental preeclampsia.
The course administration of asialized erythropoietin 
led to dose-dependent protective effects, which resulted in 
the correction of morphofunctional disorders arising from 
this experimental pathology. There was a decrease in blood 
pressure, an improvement in the placental microcircula-
tion, a noticeable restoration of the regulatory mechanisms 
of vascular tone, a decrease in proteinuria, a decrease in 
swelling of the omentum, and a decrease in morphological 
abnormalities of the ischemic genesis in the placenta.
The presence of pronounced protective effects of asial-
ized erythropoietin can be explained by the ability to bind 
to the erythropoietin heterodimeric receptor in the absence 
of an erythropoietic effect (Joshi et al. 2010; Mofidi et al. 
2011; Kaneko et al. 2013). This is confirmed in the ex-
periments on various organs and tissues and is explained 
by anti-apoptotic and antioxidant properties, the ability to 
restore the endothelial function (Joshi et al. 2010; Ishii 
et al. 2012; Kaneko et al. 2013; Kittur et al. 2013). The 
pronounced activity during ischemic injuries (Yanagawa 
et al. 2013) logically follows from the ability to activate, 
like recombinant erythropoietin, the processes of natural 
cytoprotection occurring in ischemic preconditioning. 
Based on this, it is fair to assume that the effects observed 
upon administration of recombinant erythropoietin to rats 
with ADMA-like preeclampsia could be expected from 
asialized erythropoietin (Gureev 2016).
Positive effects are associated with blockade of the en-
zyme – arginase II. The potential effects of the blockade 
of this enzyme have been confirmed in many experiments 
(Xiong et al. 2014; Sobolev et al. 2018). It was fair to ex-
pect that the positive effects obtained in the correction of 
morphofunctional disorders of ADMA-like preeclampsia 
by other arginase II inhibitors would be found in the stud-
ied pharmacological agents (Gureev et al. 2015; Nguyen 
et al. 2016; Severinova et al. 2019).
The administration of the studied pharmacological 
agents in various combinations led to a more pronounced 
correction of morphofunctional disorders in ADMA-like 
preeclampsia. This is explained by the fact that the used 
pharmacological agents, having various mechanisms of 
action, affect a greater number of pathogenetic points.
Thus, the administration of the drugs with a different 
mechanism of action to animals with ADMA-like preec-
lampsia leads to more pronounced protective effects com-
pared to the groups in which these drugs were used in a 
monotherapy. It is logical that the use of new pharma-
cological agents in complex therapy for the treatment of 
preeclampsia is most appropriate and has great prospects 
for further research.
1. The use of asialized erythropoietin at the doses of 
0.4 μg/kg and 2.4 μg/kg is accompanied by a pos-
itive dynamics of morphofunctional disorders in 
experimental preeclampsia, which is expressed in a 
decrease in blood pressure, a decrease in CED by 
about 1.5 and 2 times, respectively, an increase in 
microcirculatory indicators by 1.7 and 2 times, a 
decrease in proteinuria by 31% and 49%, and an in-
crease in the concentration of terminal metabolites 
of nitric oxide in blood plasma by 20% and 30%.
2. The use of arginase II selective inhibitors: KUD-
259 and KUD-974 – at a dose of 1 mg/kg in exper-
imental preeclampsia is accompanied by a positive 
dynamics of morphofunctional disorders, which is 
manifested in a decrease in blood pressure under 
the influence of KUD-974, a decrease in CED by 
about 2 times, and a 1.9-time increase in indicators 
of microcirculation, a decrease in proteinuria by 
63% and 56%, and an increase in the concentration 
of final metabolites of nitric oxide in blood plasma 
by 25% and 44%.
3. The combined use of arginase II selective inhibitor 
KUD-974 and asialized erythropoietin with meth-
yldopa (2 × 0.043 g/kg/day) is accompanied by a 
positive dynamics of morphofunctional disorders, 
which is manifested in a decrease in blood pressure 
which is more pronounced in the combination of 
KUD-974 with methyldopa, and a decrease in CED 
by about 2.2 and 2.4 times, an increase in microcir-
culation to the level of the intact animals, a decrease 
in proteinuria and an increase in the concentration 
of terminal metabolites of nitric oxide in blood plas-
ma to the level of the intact animals.
4. The combined use of arginase II selective inhibitor 
KUD-974 with asialized erythropoietin in experi-
mental pre-eclampsia is accompanied by a positive 
dynamics of morphofunctional disorders, which is 
manifested in a decrease in blood pressure, a decrease 
in CED by about 2.4 times, an increase in microcir-
culation, a decrease in proteinuria, and an increase in 
the concentration of terminal nitric oxide metabolites 
in blood plasma to the level of the intact animals.
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